The Federal Medical and Biological Agency (FMBA) of Russia received a Coronavirus medicine patent, which can be administered through the nose or inhalation. This is reported on the website of the organization.
We are talking about the preparation “Mir-19”, designed on behalf of the head of the FMBA Veroniki Skvortsova. “Mir-19” is a unique drug based on the use of microrn. It is safe for a person, does not affect the human genome and immunity, but at the same time highly efficient “turns off” copying (replication) of the virus and prevents the most severe forms of coronavirus infection, in including prevents pneumonites, sharp respiratory distress syndromes against a coronavirus infection, “Skvortsova said.
The Agency also reported that on April 10 in the authoritative European scientific journal of the European Academy of Allergology and Clinical Immunology (EAACI) “Allergy: European Journal of Allergy and Clinical Immunology” An article of employees “Institute of Immunology” FMBA “was published inhibition of SARS-COV reproduction -2 Modified MirNNA preparation in a complex with dendrimeric peptide. ” It describes the therapeutic strategy for COVID-19, “based on the inhalation of modified MirNNA in a complex with dendrimeric peptide.”